(Total Views: 856)
Posted On: 10/14/2020 4:06:33 PM
Post# of 151614
Dr. Seethamraju stated in his presentation from Oct. 7 that DSMB and FDA evaluating unblinded interim CD12 data.
If the data did not amount to much, there would be no need to meet with FDA.
My opinion only, but seems positive.
If the data did not amount to much, there would be no need to meet with FDA.
My opinion only, but seems positive.
(2)
(0)Scroll down for more posts ▼
